The drug roster
40 medicines and 5 combination regimens. Class, physiology and reference records are kept out of this roster.
GLP-1 receptor agonists
18 agentsSemaglutide
MARKETEDGLP-1 receptor agonist
Liraglutide
MARKETEDGLP-1 receptor agonist
Dulaglutide
MARKETEDGLP-1 receptor agonist
Exenatide
MIXED STATUSExendin-4-based GLP-1 receptor agonist
Ecnoglutide
MARKETEDLong-acting cAMP-biased GLP-1 receptor agonist
LY3537021
INVESTIGATIONALSelective long-acting GIP receptor agonist
Lixisenatide
WITHDRAWNExendin-4-based GLP-1 receptor agonist
Albiglutide
WITHDRAWNGLP-1 receptor agonist
Efpeglenatide
INVESTIGATIONALExendin-based GLP-1 receptor agonist
Monlunabant
INVESTIGATIONALPeripherally restricted cannabinoid CB1 receptor inverse agonist
Bimagrumab
INVESTIGATIONALActivin type II receptor monoclonal antibody
LY3463251
DISCONTINUEDLong-acting GDF15 receptor agonist acting through GFRAL and RET
Resmetirom
MARKETEDThyroid hormone receptor beta agonist
Setmelanotide
MARKETEDMelanocortin-4 receptor agonist
Apitegromab
INVESTIGATIONALMonoclonal antibody that inhibits activation of pro- and latent myostatin
Enobosarm
INVESTIGATIONALSelective androgen receptor modulator
Garetosmab
INVESTIGATIONALActivin A monoclonal antibody
Trevogrumab
INVESTIGATIONALMyostatin monoclonal antibody
Oral and small-molecule GLP-1
6 agentsOrforglipron
MARKETEDOral non-peptide GLP-1 receptor agonist
Danuglipron
DISCONTINUEDOral non-peptide GLP-1 receptor agonist
Aleniglipron
INVESTIGATIONALOral non-peptide GLP-1 receptor agonist
TERN-601
DISCONTINUEDOral non-peptide GLP-1 receptor agonist
Lotiglipron
DISCONTINUEDOral non-peptide GLP-1 receptor agonist
Elecoglipron
INVESTIGATIONALOral non-peptide GLP-1 receptor agonist
Combination regimens
5 agentsCagriSema
INVESTIGATIONALLong-acting amylin analogue combined with GLP-1 receptor agonism
Bimagrumab plus semaglutide
INVESTIGATIONALActivin type II receptor inhibition combined with GLP-1 receptor agonism
Apitegromab plus tirzepatide
INVESTIGATIONALMyostatin inhibition combined with GIP and GLP-1 receptor agonism
Enobosarm plus semaglutide
INVESTIGATIONALSelective androgen receptor modulation combined with GLP-1 receptor agonism
Trevogrumab plus semaglutide
INVESTIGATIONALMyostatin inhibition combined with GLP-1 receptor agonism
GLP-1 / glucagon dual agonists
5 agentsCotadutide
DISCONTINUEDGLP-1 and glucagon receptor dual agonist
Survodutide
INVESTIGATIONALGlucagon and GLP-1 receptor dual agonist
Pemvidutide
INVESTIGATIONALGLP-1 and glucagon receptor dual agonist
Mazdutide
MARKETEDGLP-1 and glucagon receptor dual agonist
Efinopegdutide
INVESTIGATIONALGLP-1 and glucagon receptor dual agonist
GIP / GLP-1 dual agonists
4 agentsTirzepatide
MARKETEDGIP and GLP-1 receptor dual agonist
MariTide
INVESTIGATIONALGLP-1 receptor agonist and GIP receptor antagonist peptide-antibody conjugate
Enicepatide
INVESTIGATIONALGIP and GLP-1 receptor dual agonist
BI 3034701
INVESTIGATIONALGLP-1, GIP and neuropeptide Y2 receptor triple agonist